KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsShares Issued
Ratios

Recursion Pharmaceuticals (RXRX) Long-Term Debt Repayments (2020 - 2025)

Historic Long-Term Debt Repayments for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $2.1 million.

  • Recursion Pharmaceuticals' Long-Term Debt Repayments fell 699.61% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.4 million, marking a year-over-year increase of 17560.17%. This contributed to the annual value of $4.4 million for FY2024, which is 47963.45% up from last year.
  • According to the latest figures from Q3 2025, Recursion Pharmaceuticals' Long-Term Debt Repayments is $2.1 million, which was down 699.61% from $2.1 million recorded in Q2 2025.
  • Recursion Pharmaceuticals' Long-Term Debt Repayments' 5-year high stood at $12.7 million during Q3 2021, with a 5-year trough of $20000.0 in Q1 2021.
  • Its 5-year average for Long-Term Debt Repayments is $1.3 million, with a median of $24000.0 in 2023.
  • Its Long-Term Debt Repayments has fluctuated over the past 5 years, first surged by 6358500.0% in 2021, then plummeted by 9981.94% in 2022.
  • Over the past 5 years, Recursion Pharmaceuticals' Long-Term Debt Repayments (Quarter) stood at $21000.0 in 2021, then increased by 9.52% to $23000.0 in 2022, then skyrocketed by 2917.39% to $694000.0 in 2023, then surged by 202.74% to $2.1 million in 2024, then increased by 1.24% to $2.1 million in 2025.
  • Its Long-Term Debt Repayments stands at $2.1 million for Q3 2025, versus $2.1 million for Q2 2025 and $2.0 million for Q1 2025.